Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cytokinetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Cytokinetics Enters Into Licensing Agreement With Astellas Pharma For CK-2127107 11
Astellas Pharma Expands Licensing Agreement with Cytokinetics 13
Equity Offering 15
Cytokinetics Plans to Raise Funds through Public Offering of Securities 15
Cytokinetics Prices Public Offering of Shares for USD75 Million 16
Cytokinetics to Raise up to USD40 Million in Public Offering of Shares 17
Cytokinetics Raises USD10 Million in Private Placement of Shares 18
Cytokinetics Completes Public Offering Of Shares For US$40.3 Million 19
Cytokinetics Completes Public Offering Of Shares For US$5 Million 21
Cytokinetics Completes Public Offering Of Common Stock And Warrants For US$42.5 Million 22
Cytokinetics Completes Public Offering Of Preferred Stock And Warrants For US$17.5 Million 24
Cytokinetics Inc – Key Competitors 26
Cytokinetics Inc – Key Employees 27
Cytokinetics Inc – Locations And Subsidiaries 28
Head Office 28
Recent Developments 29
Financial Announcements 29
Nov 01, 2018: Cytokinetics reports third quarter 2018 financial results 29
Jul 26, 2018: Cytokinetics Reports Second Quarter 2018 Financial Results 31
Apr 26, 2018: Cytokinetics Reports First Quarter 2018 Financial Results 34
Feb 15, 2018: Cytokinetics Reports Fourth Quarter 2017 Financial Results 36
Oct 26, 2017: Cytokinetics Reports Third Quarter 2017 Financial Results 38
Aug 02, 2017: Cytokinetics Reports Second Quarter 2017 Financial Results 40
Apr 27, 2017: Cytokinetics Reports First Quarter 2017 Financial Results 42
Feb 16, 2017: Cytokinetics Reports Fourth Quarter 2016 Financial Results 44
Corporate Communications 47
Feb 12, 2018: Cytokinetics Appoints Robert Califf, M.D., to Board of Directors 47
Product News 48
Nov 30, 2017: New Publication Shows Respiratory Decline Correlated With Disease Progression in People Living With ALS 48
Product Approvals 49
May 15, 2017: Cytokinetics Announces Orphan Drug Designation for CK-2127107 for the Treatment of Spinal Muscular Atrophy 49
Clinical Trials 50
Apr 24, 2018: Cytokinetics Announces Presentation of Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy at the 2018 Annual Cure SMA Conference 50
Feb 21, 2018: Phase 2 Clinical Trial Results for CK-2127107 Expected in Second Quarter of 2018 51
Jan 03, 2018: Cytokinetics Provides on CK-2127107 52
Dec 11, 2017: Cytokinetics Publishes Clinical Trial Data for CK-2127107 53
Nov 30, 2017: New Publication Summarizes Phase 1 Studies Of CK-2127107 Showing Tolerability And Amplification Of Skeletal Muscle Response To Nerve Activation 54
Jul 27, 2017: Cytokinetics Announces Start of FORTITUDE-ALS, a Phase 2 Clinical Trial of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis 56
Jul 05, 2017: Cytokinetics Announces Baseline Data From First Cohort of Phase 2 Clinical Trial of CK-2127107 in Patients With SMA 57
Mar 29, 2017: Cytokinetics Announces Start of Second Cohort in Phase 2 Clinical Trial of CK-2127107 in Patients With Spinal Muscular Atrophy 59
Mar 22, 2017: Cytokinetics Announces Preclinical Data for CK-2127107 Presented at MDA Scientific Conference 60
Appendix 61
Methodology 61
About GlobalData 61
Contact Us 61
Disclaimer 61
Cytokinetics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cytokinetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cytokinetics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cytokinetics Enters Into Licensing Agreement With Astellas Pharma For CK-2127107 11
Astellas Pharma Expands Licensing Agreement with Cytokinetics 13
Cytokinetics Plans to Raise Funds through Public Offering of Securities 15
Cytokinetics Prices Public Offering of Shares for USD75 Million 16
Cytokinetics to Raise up to USD40 Million in Public Offering of Shares 17
Cytokinetics Raises USD10 Million in Private Placement of Shares 18
Cytokinetics Completes Public Offering Of Shares For US$40.3 Million 19
Cytokinetics Completes Public Offering Of Shares For US$5 Million 21
Cytokinetics Completes Public Offering Of Common Stock And Warrants For US$42.5 Million 22
Cytokinetics Completes Public Offering Of Preferred Stock And Warrants For US$17.5 Million 24
Cytokinetics Inc, Key Competitors 26
Cytokinetics Inc, Key Employees 27
List of Figures
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9